

RHEUMATOID/PSORIATIC ARTHRITIS REFERRAL FORM (A-E)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION				
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN
Address		City	State	ZIP
Email	Home Phone	Work Phone	Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT				
Primary Caregiver/Alt Contact Name (If applicable)		Alt Contact Email	Alt Contact Phone	
PRESCRIBER INFORMATION				
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax	
Referral Contact Email		Office Phone	Office Fax	
Practice / Facility Name		Prescriber Name / Specialty		
Address		City	State	ZIP
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #	
* Please include a copy of the front and back of insurance card *				
CLINICAL INFORMATION - Please include applicable clinical chart notes				
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No		TB Skin Test Result:	Result Date:	
Other/Concomitant Medications (please list)				
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)		<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)				
ICD-10 Code <input type="checkbox"/> L40.50 Arthropathic Psoriasis <input type="checkbox"/> M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy <input type="checkbox"/> M08.3 Juvenile rheumatoid polyarthritis <input type="checkbox"/> M06.9 Rheumatoid arthritis, unspecified <input type="checkbox"/> Other _____				
PRESCRIPTION INFORMATION - Please Escribe if required by state law				
<i>In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.</i>				
MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Actemra® IV Administration Current Weight: _____kg	<input type="checkbox"/> 80 mg Vial <input type="checkbox"/> 200 mg Vial <input type="checkbox"/> 400 mg Vial	<input type="checkbox"/> Induction dose: Infuse 4 mg/kg IV once every 4 weeks <input type="checkbox"/> Maintenance Dose: Infuse 8mg/kg IV once every 4 weeks <input type="checkbox"/> Other: _____	4-week supply	
<input type="checkbox"/> Actemra® SubQ Administration Current Weight: _____kg	<input type="checkbox"/> 162 mg/0.9ml PFS <input type="checkbox"/> 162 mg/0.9ml ACTPen Autoinjector	<100 kg: <input type="checkbox"/> Inject 162 mg SubQ once every OTHER week <input type="checkbox"/> Inject 162 mg SubQ once every week (increase based on clinical results) >100 kg: <input type="checkbox"/> Inject 162 mg SubQ once every week	2 4	
<input type="checkbox"/> Cimzia® <i>Note: Lyophilized powder vials should be prepared and administered by a health care professional.</i>	Initial Dose: <input type="checkbox"/> 200 mg/ml PFS <input type="checkbox"/> 200 mg Lyophilized powder vial Maintenance Dose: <input type="checkbox"/> 200 mg/ml PFS <input type="checkbox"/> 200 mg Lyophilized powder vial	<input type="checkbox"/> Initial Dose: Inject 400 mg (2x200 mg injections) SubQ at Weeks 0, 2 and 4 Maintenance Dose: <input type="checkbox"/> Inject 200 mg SubQ every OTHER week <input type="checkbox"/> Inject 400 mg (2x200 mg injections) SubQ every 4 weeks	6 4-week supply	
<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 75 mg/0.5 mL PFS <input type="checkbox"/> 150 mg/ml PFS <input type="checkbox"/> 150 mg/ml Sensoready Pen	Loading Dose: <input type="checkbox"/> Inject 75 mg SubQ once weekly at Weeks 0, 1, 2, 3 and 4 <input type="checkbox"/> Inject 150 mg SubQ once weekly at Weeks 0, 1, 2, 3 and 4 <input type="checkbox"/> Inject 300 mg (2x150 mg injections) SubQ once weekly at Weeks 0, 1, 2, 3 and 4 Maintenance Dose: <input type="checkbox"/> Inject 75 mg SubQ once every 4 weeks <input type="checkbox"/> Inject 150 mg SubQ once every 4 weeks <input type="checkbox"/> Inject 300 mg (2x150 mg injections) SubQ once every 4 weeks	5 10 4-week supply	
<input type="checkbox"/> Enbrel® Adult Dosing	<input type="checkbox"/> 50 mg/ml Sureclick™ Autoinjector <input type="checkbox"/> 50 mg/ml PFS <input type="checkbox"/> 50 mg/ml Mini Cartridge <input type="checkbox"/> 25 mg Vial (inj supplies included) <input type="checkbox"/> 25 mg /0.5 ml PFS	<input type="checkbox"/> Inject 25 mg SubQ twice a week (72 - 96 hours apart) <input type="checkbox"/> Other: _____	4-week supply	
<input type="checkbox"/> Enbrel® Pediatric Dosing Children ≥ 2 years old and adolescents Current Weight: _____kg	<input type="checkbox"/> 25 mg/0.5 ml PFS <input type="checkbox"/> 25 mg Vial (inj supplies included) <input type="checkbox"/> 50 mg/ml PFS <input type="checkbox"/> 50 mg /ml Sureclick™ Autoinjector	<63 kg (138 pounds): <input type="checkbox"/> Inject 0.8 mg/kg/dose SubQ once a week (max dose: 50 mg/dose) >63 kg (138 pounds): <input type="checkbox"/> Inject 50 mg SubQ once a week <input type="checkbox"/> Other: _____	4-week supply	

Prescriber Signature _____ Date _____ Supervising Physician Signature (where required by state law) _____ Date _____
 DAW (Dispense as Written) _____ Date _____ Brand Necessary (must handwrite) _____

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

RHEUMATOID/PSORIATIC ARTHRITIS REFERRAL FORM (F-O)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION				
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN
Address		City	State	ZIP
Email	Home Phone	Work Phone	Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT				
Primary Caregiver/Alt Contact Name (If applicable)		Alt Contact Email	Alt Contact Phone	
PRESCRIBER INFORMATION				
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax	
Referral Contact Email		Office Phone	Office Fax	
Practice / Facility Name		Prescriber Name / Specialty		
Address		City	State	ZIP
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #	
<i>* Please include a copy of the front and back of insurance card *</i>				
CLINICAL INFORMATION - Please include applicable clinical chart notes				
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No		TB Skin Test Result:	Result Date:	
Other/Concomitant Medications (please list)				
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)		<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)				
ICD-10 Code <input type="checkbox"/> L40.50 Arthropathic Psoriasis <input type="checkbox"/> M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy <input type="checkbox"/> M08.3 Juvenile rheumatoid polyarthritis <input type="checkbox"/> M06.9 Rheumatoid arthritis, unspecified <input type="checkbox"/> Other _____				
PRESCRIPTION INFORMATION - Please Escribe if required by state law				
<i>In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.</i>				
MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Humira® Citrate Free	<input type="checkbox"/> 10 mg/0.1 mL PFS <input type="checkbox"/> 20 mg/0.2 mL PFS <input type="checkbox"/> 40 mg/0.4 mL PFS <input type="checkbox"/> 40 mg/0.4 mL Pen <input type="checkbox"/> 80 mg/0.8 mL Pen	<input type="checkbox"/> Inject 40/0.4 mL mg SubQ every OTHER week <input type="checkbox"/> Inject 40/0.4 mL mg SubQ every week <input type="checkbox"/> Inject 80/0.8 mL mg SubQ every OTHER week Polyarticular JIA: <input type="checkbox"/> 10 kg (22 lbs) to <15 kg (33 lbs): Inject 10 mg/0.1 mL SubQ every OTHER week <input type="checkbox"/> 15 kg (33 lbs) to < 30 kg (66 lbs): Inject 20 mg/0.2 mL SubQ every OTHER week <input type="checkbox"/> Weight >30 kg (66 lbs): Inject 40 mg/0.4 mL SubQ every OTHER week	4-week supply	
<input type="checkbox"/> Kevzara®	<input type="checkbox"/> 200 mg/1.14 ml PFS <input type="checkbox"/> 200mg/1.14ml Autoinjector <input type="checkbox"/> 150 mg/1.14 ml PFS <input type="checkbox"/> 150mg/1.14ml Autoinjector	<input type="checkbox"/> Inject 150 mg SubQ every 2 weeks <input type="checkbox"/> Inject 200 mg SubQ every 2 weeks	4-week supply	
<input type="checkbox"/> Methotrexate®	<input type="checkbox"/> 2.5 mg tablet	Take _____mg (_____tablets) by mouth once weekly on the same day each week	4-week supply	
	<input type="checkbox"/> 25 mg/mL (2 mL vial) Inj	Inject _____mg SQ once weekly on the same day each week	4-week supply	
<input type="checkbox"/> Olumiant	<input type="checkbox"/> 1 mg tablet <input type="checkbox"/> 2 mg tablet	<input type="checkbox"/> Take 2 mg by mouth once daily <input type="checkbox"/> Other: _____	30	
<input type="checkbox"/> Orencia® IV Administration Current Weight: _____kg	Orencia 250 mg Vial Adult: <input type="checkbox"/> <60 kg = 500 mg (2 Vials) <input type="checkbox"/> 60-100 kg = 750 mg (3 Vials) <input type="checkbox"/> >100 kg = 1,000 mg (4 Vials) Pediatric: <input type="checkbox"/> <75 kg = 10 mg/kg <input type="checkbox"/> 75-100 kg = 750 mg (3 Vials) <input type="checkbox"/> >100 kg = 1,000 mg (4 Vials)	Initial Dose: <input type="checkbox"/> Infuse _____mg IV (over 30 minutes) on Day 1, Day 15 and Day 29 Maintenance Dose: Infuse _____mg IV (over 30minutes) every 4 weeks	30	0
	<input type="checkbox"/> Orencia® SubQ Administration Current Weight: _____kg	<input type="checkbox"/> Orencia 125 mg/ml PFS <input type="checkbox"/> Orencia 125 mg/ml ClickJect™ <input type="checkbox"/> Orencia 87.5 mg/0.7 ml PFS <input type="checkbox"/> Orencia 50 mg/0.4 ml PFS	Adult Dose: <input type="checkbox"/> Inject 125 mg SubQ once weekly Pediatric Dose: (>2 years): <input type="checkbox"/> 10 to <25kg: 50 mg SubQ once weekly <input type="checkbox"/> >25 to <50kg: 87.5 mg SubQ once weekly <input type="checkbox"/> >50 kg: 125 mg SubQ once weekly	4-week supply

Prescriber Signature _____ Date _____ Supervising Physician Signature (where required by state law) _____ Date _____
 DAW (Dispense as Written) _____ Date _____ Brand Necessary (must handwrite) _____

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

Amber Enterprises, Inc., dba Amber Specialty Pharmacy © 2022

RHEUMATOID/PSORIATIC ARTHRITIS REFERRAL FORM (O-R)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION				
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN
Address		City	State	ZIP
Email	Home Phone	Work Phone	Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT				
Primary Caregiver/Alt Contact Name (If applicable)		Alt Contact Email	Alt Contact Phone	
PRESCRIBER INFORMATION				
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax	
Referral Contact Email		Office Phone	Office Fax	
Practice / Facility Name		Prescriber Name / Specialty		
Address		City	State	ZIP
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #	
* Please include a copy of the front and back of insurance card *				
CLINICAL INFORMATION - Please include applicable clinical chart notes				
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No		TB Skin Test Result:	Result Date:	
Other/Concomitant Medications (please list)				
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)		<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)				
ICD-10 Code <input type="checkbox"/> L40.50 Arthropathic Psoriasis <input type="checkbox"/> M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy <input type="checkbox"/> M08.3 Juvenile rheumatoid polyarthritis <input type="checkbox"/> M06.9 Rheumatoid arthritis, unspecified <input type="checkbox"/> Other _____				
PRESCRIPTION INFORMATION - Please Escribe if required by state law				
In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.				
MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Otezla*	<input type="checkbox"/> Starter Pack (Titration) (55 tablets)	<input type="checkbox"/> Day 1: 10 mg AM; Day 2: 10 mg BID; Day 3: 10 mg AM and 20 mg PM; Day 4: 20 mg BID; Day 5: 20 mg AM & 30 mg PM. Starting Day 6: Take one 30 mg tablet by mouth twice daily.		
	<input type="checkbox"/> Maintenance Rx 30 mg (Otezla tablets)	<input type="checkbox"/> Take one tablet by mouth twice daily <input type="checkbox"/> Other: _____		
	<input type="checkbox"/> Bridge Rx 30 mg (Otezla tablets)	<input type="checkbox"/> Take one tablet by mouth twice daily		
<input type="checkbox"/> Otrexup*	<input type="checkbox"/> 10 mg/0.4 ml <input type="checkbox"/> 20 mg/0.4 ml <input type="checkbox"/> 12.5 mg/0.4 ml <input type="checkbox"/> 22.5 mg/0.4 ml <input type="checkbox"/> 15 mg/0.4 ml <input type="checkbox"/> 25 mg/0.4 ml <input type="checkbox"/> 17.5 mg/0.4 ml	<input type="checkbox"/> Inject _____mg SQ once weekly on the same day each week	4	
<input type="checkbox"/> Rasuvo*	<input type="checkbox"/> 7.5 mg/0.15 ml <input type="checkbox"/> 20 mg/0.4 ml <input type="checkbox"/> 10 mg/0.2 ml <input type="checkbox"/> 22.5 mg/0.45 ml <input type="checkbox"/> 12.5 mg/0.25 ml <input type="checkbox"/> 25 mg/0.5 ml <input type="checkbox"/> 15 mg/0.3 ml <input type="checkbox"/> 30 mg/0.6 ml <input type="checkbox"/> 17.5 mg/0.35 ml	<input type="checkbox"/> Inject _____mg SQ once weekly on the same day each week	4	
<input type="checkbox"/> Remicade* Current Weight: _____kg	<input type="checkbox"/> 100 mg Vial	Initial Dose: Infuse 3 mg/kg (____ mg) IV at Week 0, 2 and 6 (RA) Infuse 5 mg/kg (____ mg) IV at Week 0, 2 and 6 (AS, PsA) <input type="checkbox"/> Other: _____		
Biosimilars: <input type="checkbox"/> Avsola <input type="checkbox"/> Inflectra <input type="checkbox"/> Renflexis		Maintenance Dose: Infuse 3 mg/kg (____ mg) IV every 8 weeks Infuse 10 mg/kg (____ mg) IV every 4 weeks Infuse 10 mg/kg (____ mg) IV every 8 weeks AS: Infuse 5 mg/kg (____ mg) IV every 6 weeks PsA: Infuse 5 mg/kg (____ mg) IV every 8 weeks <input type="checkbox"/> Other: _____		
<input type="checkbox"/> Rinvoq	<input type="checkbox"/> 15 mg	<input type="checkbox"/> Take one 15 mg tablet by mouth once daily		

Prescriber Signature _____ Date _____ Supervising Physician Signature (where required by state law) _____ Date _____

DAW (Dispense as Written) _____ Date _____ Brand Necessary (must handwrite) _____

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

RHEUMATOID/PSORIATIC ARTHRITIS REFERRAL FORM (S-T)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION				
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN
Address		City	State	ZIP
Email	Home Phone	Work Phone	Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT				
Primary Caregiver/Alt Contact Name (If applicable)		Alt Contact Email	Alt Contact Phone	
PRESCRIBER INFORMATION				
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax	
Referral Contact Email		Office Phone	Office Fax	
Practice / Facility Name		Prescriber Name / Specialty		
Address		City	State	ZIP
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #	
<i>* Please include a copy of the front and back of insurance card *</i>				
CLINICAL INFORMATION - Please include applicable clinical chart notes				
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>				Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No		TB Skin Test Result:	Result Date:	
Other/Concomitant Medications (please list)				
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)		<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)				
ICD-10 Code <input type="checkbox"/> L40.50 Arthropathic Psoriasis <input type="checkbox"/> M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy <input type="checkbox"/> M08.3 Juvenile rheumatoid polyarthritis <input type="checkbox"/> M06.9 Rheumatoid arthritis, unspecified <input type="checkbox"/> Other _____				
PRESCRIPTION INFORMATION - Please Escribe if required by state law				
<i>In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.</i>				
MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Simponi [®]	<input type="checkbox"/> 50 mg/0.5 ml SmartJect [®] Autoinjector <input type="checkbox"/> 50 mg/0.5 ml PFS	<input type="checkbox"/> Inject 50mg SubQ once a month	1 month supply	
<input type="checkbox"/> Simponi Aria [®] Current Weight: _____kg	<input type="checkbox"/> 50 mg/4 ml Vial	Adult Dosing, Induction Dose: Infuse 2 mg/kg (_____ mg) IV at Week 0 and Week 4 Adult Dosing, Maintenance Dose: Infuse 2 mg/kg (_____ mg) IV every 8 weeks Pediatric Dosing (Children >2 years and Adolescents), Induction Dose: Infuse 2 mg/kg (_____ mg) IV at Week 0 and Week 4 Pediatric Dosing (Children >2 years and Adolescents), Maintenance Dose: Infuse 2 mg/kg (_____ mg) IV every 8 weeks Other Dosing: _____		
<input type="checkbox"/> Stelara Current Weight: _____kg <i>(recommended dose for coexistent PsA & PsO in patients >100kg = 90mg)</i>	<input type="checkbox"/> 45 mg/0.5 ml PFS <input type="checkbox"/> 90 mg/1 ml PFS	Induction Dose: <input type="checkbox"/> Inject 45 mg SubQ on day 1 <input type="checkbox"/> Inject 90 mg SubQ on day 1 Maintenance Dose: <input type="checkbox"/> Inject 45 mg SubQ on day 29 and every 12 weeks thereafter <input type="checkbox"/> Inject 90 mg SubQ on day 29 and every 12 weeks thereafter		
<input type="checkbox"/> Taltz [®]	<input type="checkbox"/> 80 mg/ml PFS <input type="checkbox"/> 80 mg/ml Pen	Induction Dose (Psoriatic Arthritis): <input type="checkbox"/> Inject 160mg (2x80mg) SubQ once at week 0 Induction Dose (Psoriasis or Psoriatic Arthritis with coexisting Psoriasis): <input type="checkbox"/> Inject 160mg (2x80mg) SubQ at week 0, followed by 80mg SubQ at week 2 <input type="checkbox"/> Inject 80mg SubQ at week 4 and every 2 weeks thereafter through week 10 <input type="checkbox"/> Inject 80mg SubQ at week 12 and every 4 weeks thereafter Maintenance Dose (Psoriasis/Psoriatic Arthritis/Psoriatic Arthritis w/ coexisting Psoriasis): <input type="checkbox"/> Inject 80mg SubQ every 4 weeks	4 week supply	
<input type="checkbox"/> Tremfya	<input type="checkbox"/> 100 mg/mL prefilled syringe <input type="checkbox"/> 100 mg/mL one-press injector	<input type="checkbox"/> Induction Dose: inject 100mg SubQ at week 0 and week 4 (2 syringes/pens) <input type="checkbox"/> Maintenance Dose: Inject 100mg SubQ once every 8 weeks		

Prescriber Signature _____ Date _____ Supervising Physician Signature (where required by state law) _____ Date _____
 DAW (Dispense as Written) _____ Date _____ Brand Necessary (must handwrite) _____

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

Amber Enterprises, Inc., dba Amber Specialty Pharmacy © 2022

RHEUMATOID/PSORIATIC ARTHRITIS REFERRAL FORM (U-Z)

PHONE 888.370.1724 | FAX 877.645.7514



Remove above portion before faxing. Please complete the prescription form in its entirety and fax with secure cover sheet to the number above.

PATIENT INFORMATION					
Last Name	First Name	DOB	Gender <input type="checkbox"/> M <input type="checkbox"/> F	Last 4 SSN	Primary Language
Address			City	State	ZIP
Email		Home Phone	Work Phone	Cell Phone	
Primary Contact Method (check one) <input type="checkbox"/> Cell Phone <input type="checkbox"/> Home Phone <input type="checkbox"/> Work Phone <input type="checkbox"/> Text <input type="checkbox"/> Email <input type="checkbox"/> Primary Caregiver <input type="checkbox"/> DO NOT CONTACT					
Primary Caregiver/Alt Contact Name (If applicable)			Alt Contact Email	Alt Contact Phone	

PRESCRIBER INFORMATION					
Name of Contact Sending Referral		Title	Preferred Contact Method (check one) <input type="checkbox"/> Email <input type="checkbox"/> Phone <input type="checkbox"/> Fax		
Referral Contact Email			Office Phone	Office Fax	
Practice / Facility Name			Prescriber Name / Specialty		
Address			City	State	ZIP
Prescriber State License #	DEA #	NPI #	Medicaid UPIN #		

*** Please include a copy of the front and back of insurance card ***

CLINICAL INFORMATION - Please include applicable clinical chart notes					
Patient New to Therapy <input type="checkbox"/> Naïve/New Start <input type="checkbox"/> Therapy Restart <input type="checkbox"/> Existing Treatment <input type="checkbox"/>					Therapy Start Date
Sample/Starter Provided? <input type="checkbox"/> No <input type="checkbox"/> Yes, Provide Qty:	Date Provided:	Patient Height (cm/in):	Weight (kg/lbs):	Date Obtained:	
If Self-injectable drug, is injection training coordination required by our pharmacy? <input type="checkbox"/> Yes <input type="checkbox"/> No			TB Skin Test Result:	Result Date:	
Other/Concomitant Medications (please list)					
Allergies <input type="checkbox"/> NKDA <input type="checkbox"/> Drug Allergies (please list)			<input type="checkbox"/> Other Allergies (please list)		
Ship to Address <input type="checkbox"/> Home <input type="checkbox"/> Prescriber's Office <input type="checkbox"/> Other (please list)					
ICD-10 Code <input type="checkbox"/> L40.50 Arthropathic Psoriasis <input type="checkbox"/> M08.00 Unspecified juvenile rheumatoid arthritis of unspecified site <input type="checkbox"/> L40.59 Other Psoriatic Arthropathy <input type="checkbox"/> M08.3 Juvenile rheumatoid polyarthritis <input type="checkbox"/> M06.9 Rheumatoid arthritis, unspecified <input type="checkbox"/> Other _____					

PRESCRIPTION INFORMATION - Please Escribe if required by state law				
<i>In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary," or your state-specific required language to prohibit substitutions. This form is not a valid prescription form for writing controlled medications.</i>				
MEDICATION	DOSE	DIRECTIONS	QTY	REFILLS
<input type="checkbox"/> Xatmep'	<input type="checkbox"/> 2.5 mg/ml oral solution	<input type="checkbox"/> Take _____mg one time weekly	1 month	
<input type="checkbox"/> Xeljanz'	<input type="checkbox"/> 5 mg tablet	<input type="checkbox"/> Take one tablet by mouth once daily	60	
<input type="checkbox"/> Xeljanz XR'	<input type="checkbox"/> 11 mg XR tablet	<input type="checkbox"/> Take one tablet by mouth once daily	30	

_____ Prescriber Signature	_____ Date	_____ Supervising Physician Signature (where required by state law)	_____ Date
_____ DAW (Dispense as Written)	_____ Date	_____ Brand Necessary (must handwrite)	

Note: The information contained in this document will become a legal prescription. Prescriber is to comply with his/her state specific Pharmacy and Medical Board guidelines such as e-prescribing, state specific prescription form, fax language, number of prescriptions allowed on a single prescription form, etc. If more than one page is required, make additional copies. Non-compliance with state specific requirements could result in outreach to the prescriber.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.

Amber Enterprises, Inc., dba Amber Specialty Pharmacy © 2022